ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia prnasia
December 16, 2019CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received the approval from the Human Research Ethics Committee (HREC) in Australia, and the acknowledgement from Australia's Therapeutic Goods Adm
Pharma Sources Insight July 2025
